Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Ariel-university Research and Development Company Ltd.

Esther Fride

Raphael Mechoulam

Aviva Breuer

Esther Shohami

Ruth Gallily

Yinon Ben Neriah

Shimon Ben Shabat

Tzviel Sheskin

Arik Moussaieff

The present invention relates to a compound of the general formula (I) which is a non-hydrolysable analogue of endogenous cannabinoids, which are found to be more potent therapeutic agents as they are more stable, for example, to hydrolytic cleavage in the gastrointestinal tract. The cannabinoid analogues of the invention have a therapeutic value. Therefore, pharmaceutical compositions comprising as active ingredient a therapeutically effective amount of at least one compound of the invention may be prepared. Such compositions may be used as anti-inflammatory, anti-asthmatic, analgetic, hypotensive, antiemetic or anti-spasmodic compositions, and as compositions for treating and/or preventing glaucoma or migraine, or as compositions for relieving symptoms of multiple sclerosis and mood stimulating compositions.

Synthetic endogenous cannabinoids analogues and uses thereof

Growing community of inventors

Efrat, Israel

Esther Fride